<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564327</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-03/MG-02</org_study_id>
    <nct_id>NCT03564327</nct_id>
  </id_info>
  <brief_title>Clinical Prognosis of Patients With Atrial Fibrillation Non-reducible or Non-inducible During Radiofrequency Ablation</brief_title>
  <acronym>Isochrone-AFAn</acronym>
  <official_title>Clinical Prognosis of Patients With Atrial Fibrillation Non-reducible or Non-inducible During Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an ancillary study to Isochrone-AF. The investigators hypothesize that patients
      eligible but non-included in the primary study (patients classified as non-reducible or
      non-inducible) will have different prognosis and electro-physiclogical characteristics to the
      patients included and randomized into the Isochrone AF study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation relapse in non-reducible or non-inducible patients</measure>
    <time_frame>Month 18</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation relapse in non-reducible or non-inducible patients</measure>
    <time_frame>Month 12</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia occurrence in non-reducible or non-inducible patients</measure>
    <time_frame>Month 12</time_frame>
    <description>Arrhythmia, including atrial tachycardia detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia occurrence in non-reducible or non-inducible patients</measure>
    <time_frame>Month 18</time_frame>
    <description>Arrhythmia, including atrial tachycardia detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of zones of low voltage on voltage maps in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of zones of anisochronic zones on voltage maps in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum variation of conduction speed in the same anatomic region in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreasing velocities in the same anatomic region in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wave front rotation in the same anatomic region in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time of radiofrequency in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of lesion volume in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>Force-time integral, lesion size index or stroke volume index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and size of treated zones by guided versus conventional ablation in non-inducible patients</measure>
    <time_frame>Day 0</time_frame>
    <description>cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>List locations most frequently treated</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of each</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without relapse of patients treated using the Carto- vs Rhythmia-guided ablation approaches in non-reducible or non-inducible patients</measure>
    <time_frame>Month 18</time_frame>
    <description>Atrial fibrillation detected by routine or event-associated Holter examination</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients with sinus rhythm</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with atrial fibrillation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wide antrum circle ablation</intervention_name>
    <description>As standard hospital policy</description>
    <arm_group_label>Patients with sinus rhythm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>External electric cardioversion</intervention_name>
    <description>Three attempts (200-250 joules)</description>
    <arm_group_label>patients with atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the CHU Nimes and Montpellier for scheduled ablation of paroxysmal or
        persistent atrial fibrillation by radiofrequency using an electro-anatomical navigation
        system who are eligible but non-included in the study ISOCHRONE-AF due to non-reducible or
        non-inducible atrial fibrillation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient is at least 18 years old

          -  The patient is available for 18 month follow-up

          -  The patient has paroxysmal or persistent atrial fibrillation which is:

               -  Non-reducible following external electric cardioversion; or

               -  Non-inducible following wide antrum circle ablation

        Exclusion Criteria:

          -  The subject is participating in a category 1 interventional study, or is in a period
             of exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  The patient is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu Granier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Granier, MD</last_name>
    <phone>04.67.33.67.33</phone>
    <email>m-granier@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Granier, MD</last_name>
      <phone>04.67.33.67.33</phone>
      <email>m-granier@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Granier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Massin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc Pasquie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-François Winum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

